The significance of FOXP1 in diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of mature B-cell lymphoma. While the majority of patients are cured with immunochemotherapy incorporating the anti-CD20 monoclonal antibody rituximab (R-CHOP), relapsed and refractory patients still have a dismal prognosis. DLBCL subty...
Main Authors: | Gascoyne, D, Banham, A |
---|---|
Format: | Journal article |
Published: |
Taylor and Francis
2016
|
Similar Items
-
Identification of FOXP1 Transcriptional Targets in Diffuse Large B Cell Lymphoma
by: Camilleri, E, et al.
Published: (2012) -
Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma.
by: Banham, A, et al.
Published: (2005) -
FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas
by: Brown, P, et al.
Published: (2015) -
FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures
by: Wong, K, et al.
Published: (2016) -
Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients
by: Wong, K, et al.
Published: (2014)